Lecithins, egg
Based on 1 publication(s) in Google Scholar
Lecithins, egg (Lecithins, egg yolk; Belovo PL 85) is an orally active natural phospholipid mixture extracted from egg yolks. Lecithins, egg inhibits the activities of acetylcholinesterase (AChE) and angiotensin-converting enzyme (ACE). Lecithins, egg exhibits antibacterial, antioxidant and anti-inflammatory activities, and helps delay cellular senescence. Lecithins, egg enhances nerve conduction, improves memory and cognitive function, and exerts positive effects on delaying neurodegenerative diseases. Lecithins, egg promotes lipid absorption and alleviates diarrhea. Lecithins, egg acts as a high-efficiency drug carrier for the preparation of targeted drug delivery systems such as liposomes.
For research use only. We do not sell to patients.
- Purity : 99.0%
- CAS No.: 93685-90-6
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Lecithins, egg
More
Biological Activity
Description
In Vitro
Lecithins, egg (1.2 mmol/L) inhibits cholesterol absorption and transport in Caco-2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Enteral emulsion containing Lecithins, egg (10 g/kg; p.o.; single administration) significantly improves lipid absorption in bile duct-ligated rats, with an IAUC of 849.8 mg/dL × h that is higher than that of soybean lecithin[2].
Enteral formula containing Lecithins, egg (0.6%; p.o.; ad libitum for 5 days, then fixed daily amount for 5 days) significantly improves fecal consistency in Rattus norvegicus (rats) with short bowel syndrome, with lower fecal scores compared to formula without egg yolk lecithin or with added dietary fiber[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 6-week-old, 110-130 g, bile duct-ligated)[2]
-
Dosage:10 g/kg
-
Administration:p.o.; single administration
-
Result:Showed significantly higher serum triglyceride concentration at 2 hours post-administration compared to soybean lecithin and synthetic emulsifier groups.
Showed significantly higher serum triglyceride concentration at 4 hours post-administration compared to soybean lecithin group.
Achieved an IAUC for serum triglycerides of 849.8 mg/dL × h, which was significantly higher than the soybean lecithin group's 193.6 mg/dL × h.
-
Animal Model:Sprague-Dawley (male, 7-week-old, 190-220 g, 40 cm distal small bowel resected)[2]
-
Dosage:0.6%
-
Administration:p.o.; ad libitum for 5 days, then fixed daily amount for 5 days
-
Result:Showed significantly lower fecal score compared to the dietary fiber (+) group on days 6 to 10 of test diet feeding.
Showed significantly lower fecal score compared to the egg yolk lecithin (-) group on days 4, 5, and 9.
Showed no significant difference in fecal score compared to the MCT (-) group.
Chemical Information
-
CAS No. 93685-90-6
-
Appearance Oil
-
Color Light yellow to brown
-
SMILES
[Lecithins, egg]
-
Synonyms
Lecithins, egg yolk; Belovo PL 85
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 May 1;16(1):4078. PMID: 40307217
Solvent & Solubility
In Vitro:
Ethanol : ≥ 100 mg/mL
* "≥" means soluble, but saturation unknown.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Protocol for Water Maze
The Morris Water Maze is a rodent spatial learning and memory assay in which a mouse or rat swims in opaque water to find an escape platform; in the hidden-platform version, the animal cannot see the platform and must use distal extra-maze cues to learn its fixed spatial location. The assay primarily measures hippocampus-dependent spatial learning during acquisition trials and spatial reference memory during probe trials after platform removal; readouts include escape latency, swim path length, swim speed, quadrant occupancy, platform-site crossings, and proximity to the former platform location.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (587 KB)
- English - EN (587 KB)
- Français - FR (587 KB)
- Deutsch - DE (587 KB)
- Norwegian - NO (587 KB)
- Español - ES (587 KB)
- Swedish - SV (587 KB)
- Italian - IT (587 KB)
- Korean - KR (587 KB)
- Portuguese - PT (587 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhao F, et al. Perspectives on lecithin from egg yolk: Extraction, physicochemical properties, modification, and applications. Front Nutr. 2023;9:1082671. Published 2023 Jan 6. [Content Brief]
[2]. Akashi T, et al. Enteral Formula Containing Egg Yolk Lecithin Improves Diarrhea. J Oleo Sci. 2017;66(9):1017-1027. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Lecithins, egg
- 93685-90-6
- Lecithins, egg yolk
- Belovo PL 85
- Belovo PL85
- Belovo PL 85
- Belovo PL-85
- Cholinesterase (ChE)
- Angiotensin-converting Enzyme (ACE)
- Bacterial
- metabolic syndrome
- obesity
- hypertension
- Alzheimer’s disease
- acetylcholinesterase
- hyperlipidemia
- short bowel syndrome
- coronary heart disease
- angiotensin-converting enzyme
- Caco-2 cells
- Inhibitor
- inhibitor
- inhibit